GlassScriptPhysician profile
Harry Simms Hardin
NPI 1194984096
$1,326.95
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $67.77 · 2022: $252 · 2023: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $522.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $148.78 | 2019 | |
| Siemens Medical Solutions USA, INC. | $118.23 | 2023 | Multitom Rax, Magnetom Sola, System Somatom Drive |
| Eisai INC. | $107.69 | 2019-2023 | |
| Incyte Corporation | $82.09 | 2019-2023 | Jakafi |
| Lilly USA, LLC | $72.48 | 2022-2023 | Jaypirca, Verzenio, Retevmo |
| Astrazeneca Pharmaceuticals LP | $69.88 | 2019-2023 | Tagrisso |
| Novartis Pharmaceuticals Corporation | $53.70 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $53.69 | 2022-2023 | Lynparza, Welireg, Keytruda |
| Regeneron Healthcare Solutions, INC. | $48.21 | 2022-2023 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $46.97 | 2019-2020 | |
| Seagen INC. | $45.18 | 2022-2023 | Adcetris |
| Amgen INC. | $43.53 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $41.33 | 2019-2023 | Onivyde, Somatuline Depot |
| Karyopharm Therapeutics INC. | $39.22 | 2022-2023 | Xpovio |
| Alexion Pharmaceuticals, INC. | $34.40 | 2022-2023 | Ultomiris |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $29.95 | 2019 | |
| Puma Biotechnology, INC. | $29.83 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.37 | 2023 | |
| Secura Bio, INC. | $27.30 | 2020 | |
| Spectrum Pharmaceuticals INC. | $24.35 | 2023 | Rolvedon |
| Celgene Corporation | $22.27 | 2019 | |
| Aurobindo Pharma USA, INC. | $21.49 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.68 | 2023 | Xarelto |
| Genmab U.S., INC. | $15.77 | 2023 | Tivdak |
| Genentech USA, INC. | $14.51 | 2022 | |
| Adc Therapeutics America, INC. | $14.30 | 2023 | |
| Abbvie INC. | $14.20 | 2022 | |
| Exelixis INC. | $13.17 | 2019 | |
| Sobi, INC | $13.06 | 2023 | |
| Daiichi Sankyo INC. | $12.69 | 2019 | |
| Agios Pharmaceuticals, INC. | $11.73 | 2020 | |
| Kyowa Kirin, INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Hardin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.